Actively Recruiting
Comparing Empagliflozin and Dapagliflozin for Treating Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease A Phase 4 Randomized Trial Embedded in Electronic Health Records
Led by Herlev and Gentofte Hospital · Updated on 2024-11-05
17200
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the comparative effectiveness of two drugs, empagliflozin and dapagliflozin, for treating type 2 diabetes, chronic kidney disease, and heart failure. This phase 4 clinical trial aims to understand how these medications impact important health outcomes including death, heart-related hospitalizations, and kidney problems. Participants prescribed either empagliflozin 10 mg or dapagliflozin 10 mg once daily as part of their usual care will be included. Treatment assignment is randomized automatically through electronic health records based on the time of day, allowing comparison of these two drugs in real-life clinical settings. During the study, researchers will track the time to the first occurrence of events such as death, hospitalizations for heart failure, heart attack, stroke, and worsening kidney disease up to 24 months. Secondary outcomes include other heart-related hospitalizations. Participants will be monitored through their medical records over this period to observe these health events and treatment effects.
CONDITIONS
Brief Title
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
Research Team
M
Morten Schou, Professor
D
Daniel M. Christensen, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
